Dr. David Hussong, FDA CDER, reviewed the impact that B. cepacia can have on pharmaceutical product and the reasons why this organism may be considered objectionable for certain dosage forms. He stated that current test methods, including finished product testing, may not be sufficient in detecting objectionable organisms, and that it is more critical to look for these types of organisms during in-process screening using rapid methods.
